Prognostic Factors in Locally Advanced Breast Cancer
Author Information
Author(s): AH Honkoop, PJ van Diest, JS de Jong, SC Linn, G Giaccone, K Hoekman, J Wagstaff, HM Pinedo
Primary Institution: University Hospital Vrije Universiteit
Hypothesis
What clinical, pathological, and biological characteristics predict outcomes in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy?
Conclusion
The study suggests that more chemotherapy cycles and a better pathological response are associated with improved survival in patients with locally advanced breast cancer.
Supporting Evidence
- More chemotherapy cycles were related to better disease-free survival.
- A better pathological response to chemotherapy was associated with improved overall survival.
- High levels of Ki-67 staining after chemotherapy correlated with worse prognosis.
- Co-expression of P-gp and p53 was linked to poorer outcomes.
Takeaway
This study looked at women with advanced breast cancer and found that getting more chemotherapy can help them live longer.
Methodology
Patients received neoadjuvant chemotherapy followed by mastectomy and radiotherapy, with a follow-up period of 32 months.
Potential Biases
The groups receiving different numbers of chemotherapy cycles were not randomized.
Limitations
The sample size was small, and the results should be interpreted with caution.
Participant Demographics
Patients with clinical stage IIIA or IIIB breast cancer.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website